Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

CONCLUSIONS: The Oncotype DX test could be a useful tool to select patients candidates for neoadjuvant chemotherapy in luminal breast cancer. Neoadjuvant chemotherapy could be avoided in 42% of patients. We found a correlation between Recurrence Score results and pathological response with 14% of RCB-0 and a total of 47% of significant pathological response type RCB-0 and RCB-I in patients with highest Recurrence Score results. Interestingly, patients with a Recurrence Score result inferior to 32 did not get any histological response type 0 and only 5% RCB-I.PMID:33601299 | DOI:10.1016/j.breast.2021.01.001

Source: Breast - February 18, 2021 Category: Cancer & Oncology Authors: Serafin Morales Murillo Ariadna Gasol Cudos Joel Veas Rodriguez Carles Canosa Morales Jordi Mel é Olivé Felip Vilardell Villellas Douglas Rene Sanchez Guzman Edelmiro Iglesias Mart ínez Antonieta Salud Salvia Source Type: research